High-density lipoprotein mimetics: promises and challenges

被引:27
|
作者
Sviridov, Dmitri [1 ]
Remaley, Alan T. [2 ]
机构
[1] Baker IDI Heart & Diabet Inst, Lab Lipoprot & Atherosclerosis, Melbourne, Vic 3004, Australia
[2] NHLBI, Lipoprot Sect, NIH, Bethesda, MD 20892 USA
基金
英国医学研究理事会;
关键词
apolipoproteins; atherosclerosis; cholesterolmetabolism; lipoprotein metabolism; peptides; APOLIPOPROTEIN-A-I; REVERSE CHOLESTEROL TRANSPORT; PEPTIDE; 4F; ANTIINFLAMMATORY PROPERTIES; CORONARY ATHEROSCLEROSIS; REDUCES ATHEROSCLEROSIS; AMPHIPATHIC PEPTIDES; PLASMA-CLEARANCE; LESION FORMATION; OXIDIZED LIPIDS;
D O I
10.1042/BJ20150832
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The concept of lipoprotein mimetics was developed and extensively tested in the last three decades. Most lipoprotein mimetics were designed to recreate one or several functions of high-density lipoprotein (HDL) in the context of cardiovascular disease; however, the application of this approach is much broader. Lipoprotein mimetics should not just be seen as a set of compounds aimed at replenishing a deficiency or dysfunctionality of individual elements of lipoprotein metabolism but rather as a designer concept with remarkable flexibility and numerous applications in medicine and biology. In the present review, we discuss the fundamental design principles used to create lipoprotein mimetics, mechanisms of their action, medical indications and efficacy in animal models and human studies.
引用
收藏
页码:249 / 259
页数:11
相关论文
共 50 条
  • [21] High-density lipoprotein cholesterol: origins and the path ahead
    Oda, Michael N.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2015, 22 (02) : 133 - 141
  • [22] High-density Lipoprotein (HDL) Dysfunction and the Future of HDL
    Ertek, Sibel
    CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (05) : 490 - 498
  • [23] Recombinant High-Density Lipoprotein Formulations
    Vucic, Esad
    Rosenson, Robert S.
    CURRENT ATHEROSCLEROSIS REPORTS, 2011, 13 (01) : 81 - 87
  • [24] Intrinsic enzymes of high-density lipoprotein
    Le, Ngoc-Anh
    Walter, Mary F.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2007, 1 (01) : 20 - 30
  • [25] Acute high-density lipoprotein therapies
    MyNgan Duong
    Di Bartolo, Belinda A.
    Nicholls, Stephen J.
    CURRENT OPINION IN LIPIDOLOGY, 2015, 26 (06) : 521 - 525
  • [26] High-density lipoprotein. Function and clinical importance [High-density lipoprotein: Funktion und klinische bedeutung]
    Merkel M.
    Der Diabetologe, 2012, 8 (7): : 544 - 549
  • [27] High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis
    Favari, Elda
    Thomas, Michael J.
    Sorci-Thomas, Mary G.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2018, 71 (06) : 325 - 331
  • [28] Preparation and Activity Analysis of Recombinant Human High-Density Lipoprotein
    Su, Manman
    Chang, Weiqin
    Shi, Kaiyao
    Wang, Dingding
    Wang, Mingxing
    Xu, Tianmin
    Yan, Weiqun
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2012, 10 (05) : 485 - 491
  • [29] Gene Therapy to Improve High-Density Lipoprotein Metabolism and Function
    Van Craeyveld, Eline
    Gordts, Stephanie
    Jacobs, Frank
    De Geest, Bart
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (13) : 1531 - 1544
  • [30] High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus
    He, Yi
    Kothari, Vishal
    Bornfeldt, Karin E.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (02) : e10 - e16